Kura Oncology (NASDAQ: KURA) shares KOMZIFTI revenue, 2026 goals

Rhea-AI Filing Summary

Kura Oncology, Inc. filed a current report to furnish a press release dated January 11, 2026. The press release highlights the company’s recent accomplishments, reports preliminary revenue for its product KOMZIFTI™ (ziftomenib), and outlines anticipated milestones for 2026. The press release is attached as Exhibit 99.1. The information provided under Item 2.02 and in Exhibit 99.1 is being furnished, not filed, which means it is not subject to certain liability provisions of the Securities Exchange Act and will only be incorporated into future Securities Act registration statements if specifically identified.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001422143 0001422143 2026-01-11 2026-01-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 11, 2026

KURA ONCOLOGY, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-37620		61-1547851
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
4930 Directors Place, Suite 500, San Diego, CA				92121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 500-8800

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		KURA		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 11, 2026, Kura Oncology, Inc. (the “Company”) issued a press release highlighting recent accomplishments, reporting preliminary KOMZIFTI^™ (ziftomenib) revenue and outlining anticipated 2026 milestones. A copy of this press release is furnished herewith as Exhibit 99.1.

The information contained in this Current Report on Form 8-K under Item 2.02 and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press release dated January 11, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

				KURA ONCOLOGY, INC.
Date: January 12, 2026				By:		/s/ Teresa Bair
						Teresa Bair
						Chief Legal Officer

FAQ

What did Kura Oncology (KURA) report in this 8-K filing?

Kura Oncology furnished a press release that highlights recent accomplishments, provides preliminary KOMZIFTI™ (ziftomenib) revenue, and describes anticipated milestones for 2026, attached as Exhibit 99.1.

What product revenue is discussed by Kura Oncology (KURA) in this document?

The company reports preliminary revenue for its product KOMZIFTI™ (ziftomenib) in the press release furnished as Exhibit 99.1.

Does the Kura Oncology (KURA) 8-K include information about 2026 milestones?

Yes. The press release furnished with the 8-K outlines anticipated milestones for 2026 related to Kura Oncology’s business and KOMZIFTI™ (ziftomenib).

Is the information in Kura Oncology’s press release considered filed with the SEC?

No. The information under Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not subject to Section 18 liability and will only be incorporated into registration statements if specifically identified.

Where can investors find the full details on Kura Oncology’s preliminary KOMZIFTI revenue?

Full details are contained in the press release dated January 11, 2026, which is furnished as Exhibit 99.1 to this 8-K filing.

Who signed the Kura Oncology (KURA) 8-K related to the KOMZIFTI press release?

The 8-K was signed on behalf of Kura Oncology, Inc. by Teresa Bair, the company’s Chief Legal Officer.